Anwen Liu

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

Shun Lü, Lin Wu, Hong Jian et al. · The Lancet Oncology · 2022 · 227 citations

Oncology, First Interim Results, Bevacizumab Biosimilar Ibi305 +10

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial

Shun Lü, Lin Wu, Hong Jian et al. · The Lancet Respiratory Medicine · 2023 · 181 citations

Oncology, Disease Progression, Second Interim Analysis +9

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang, Lin Wu, Baolan Li et al. · Journal of Clinical Oncology · 2022 · 161 citations · Full text

Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by <i>UGT1A1</i> Status in Patients With Locally Advanced Rectal Cancer

Ji Zhu, Anwen Liu, Xinchen Sun et al. · Journal of Clinical Oncology · 2020 · 117 citations · Full text

CXC195 suppresses proliferation and inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway

Yiting Wang, Qunfei Tu, Wei Yan et al. · Biochemical and Biophysical Research Communications · 2014 · 66 citations

Inflammation, Tlr4-myd88-tak1-mediated Nf-κb, Medicine +14